Latest News - Alnylam Pharmaceuticals
Top Corporates Hub
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns
10.07.2026 09:13
Alnylam Pharmaceuticals stock has delivered an 81.9% gain over the past 5 years, yet current valuation checks and market multiples point to a more mixed picture rather than a clear bargain. Over 5 years, Alnylam Pharmaceuticals has returned 81.9%, which sets a high bar for any further upside case. Recent clinical progress in RNAi therapies and expanded AI partnerships can support growth expectations, while competitive and clinical trial risks in key indications may still weigh on how much...
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
09.07.2026 15:35
CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump
09.07.2026 12:54
AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction
09.07.2026 12:45
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
Discover the top movers in Thursday's pre-market session.
09.07.2026 12:30
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
AstraZeneca stock drops 9% after Wainua heart drug trial fails
09.07.2026 11:14
The British drugmaker lost roughly $27 billion in market value after Wainua failed to reduce cardiovascular deaths and recurring heart events
Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook
09.07.2026 10:43
Alnylam Pharmaceuticals stands to benefit from the unexpected Phase III failure of Ionis/AstraZenecaâs eplontersen. Read why ALNY stock is a buy.
Aehr Test Systems, Lam Research, Applied Materials And Other Big Stocks Moving Higher On Thursday
09.07.2026 10:01
U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers include FBRX, BBIO, TRAX, LASR, ONTO, ALNY, ICHR, LITE, ARM, LRCX, KLAC, and FORM.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
09.07.2026 08:05
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stock
Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
09.07.2026 04:53
Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%, AIBZ +14.3%, BBIO +10%. Losers: AFJK -25.8%, VTAK -19%, APVO -18%, NQ -16.3%.
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside
08.07.2026 12:48
Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
02.07.2026 10:53
Analysts have given Alnylam Pharmaceuticals an average price target of $436.
Komodo Expands Strategic Partnership with Alnylam Pharmaceuticals, Inc. (ALNY)
02.07.2026 06:17
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the Best Fundamental Stocks. On June 25, Komodo Health expanded its strategic partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). It is an extension of work built on Komodo’s Healthcare Map and Marmot analytics AI platform, following Alnylam’s adoption of the platform in August 2025 to develop custom AI agents for its […]
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
29.06.2026 09:05
Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials, Robinhood, Liquidia, Airbnb, Praxis, Alnylam, and Uniqure.
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $470
29.06.2026 06:10
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $510 to $470.
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding Disorders - Slideshow
25.06.2026 13:43
2026-06-25. The following slide deck was published by Alnylam Pharmaceuticals, Inc.
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
25.06.2026 13:00
NEW YORK & SAN FRANCISCO, June 25, 2026--Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo’s analytics AI platform, across key enterprise functions at Alnylam.
Komodo Health Expands Strategic Partnership With Alnylam Pharma To Scale Marmot, Komodo’s Analytics AI Platform, Across Key Enterprise Functions At Alnylam
25.06.2026 09:03
Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life SciencesKomodo also unveils new Marmot capabilities to move organizations beyond
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY): A Decent Value Play with Strong Growth at a Discount to Peers
19.06.2026 10:20
Alnylam Pharmaceuticals shows strong value potential with a 7/10 valuation score, trading cheaper than 91% of peers. With 288% EPS growth and a low PEG ratio, this biotech stock offers value investors growth at a reasonable price.
Alnylam Taps Generative AI And Nordic Expansion As Market Lags Targets
14.06.2026 16:11
Alnylam Pharmaceuticals (NasdaqGS:ALNY) has entered a collaboration with Inceptive Nucleics to apply generative AI models to its RNAi research and development. The company has also expanded its commercial partnership with GENESIS Pharma to cover the Nordic countries, extending the reach of its RNAi therapies in Europe. Alnylam shares most recently closed at $282.85, with the stock down 29.3% year to date and down 8.2% over the past year. Over a 3 year period the stock is up 40.3%, and over...